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ABSTRACT:   
Background: 
Little data exist on the long-term prognosis of patients with inflammatory bowel disease 
(IBD) after stopping TNFα- blocking therapy in deep remission. Existing data indicate that 
approximately 50% of patients on combination therapy who discontinued TNFα- blockers 
are still in remission 24 months later. The aims of this follow-up analysis was to evaluate 
the long-term remission rate after cessation of TNFα-blocking therapy, the predicting 
factors of a relapse and the response to restarting TNFα blockers.  
Methods:  
The first follow-up data of 51 IBD patients (17 Crohn’s disease [CD], 30 ulcerative colitis 
[UC] and 4 inflammatory bowel disease type unclassified [IBDU]) in deep remission at the 
time of cessation of TNFα-blocking therapy have been published earlier. The long-term 
data was collected retrospectively after the first follow-up year to evaluate the remission 
rate and risk factors for the relapse after a median of 36 months.  
Results:  
After the first relapse-free year, 14 out of the remaining 34 IBD patients relapsed (41%; 5/12 
[42%] CD and 9/22 [41%] UC/IBDU). Univariate analysis indicated no associations with any 
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predictive factors. Re-treatment was effective in 90% (26/29) of patients. 
 
Conclusion:  
Of IBD patients in deep remission at the time of cessation of TNFα-blocking therapy, up to 
60% experience a clinical or endoscopic relapse after a median follow-up time of 36 months 
(95% CI 31-41 months). No individual risk factors predicting relapse could be identified. 
However, the initial response to a restart of TNFα-blockers seems to be effective and well 
tolerated.  
 
INTRODUCTION 
 
The chronic nature of inflammatory bowel disease (IBD) and lack of recommendations for 
cessation of TNFα-blocking therapy may lead to long-term maintenance therapy with 
TNFα blockers as early treatment recommendations have become more widely accepted. 
With patients achieving remission, the potential severe side effects (i.e. infections, acute 
infusion reactions, delayed hypersensitivity reactions, risk of neoplasia, and safety issues 
during pregnancy) and economic issues prompt the questions on cessation of TNFα-
blocking therapy.1,2,3,4 In addition, it is nowise certain that the benefits of TNFα-blocking 
agents are permanent in the long run.  
 
Several studies show that the overall risk of relapse after discontinuation of TNFα-blocking 
agents is 44% for Crohn's disease (CD, follow-up range of 6-125 months) and 38% for 
ulcerative colitis (UC, follow-up range of 6-24 months).5,6,7,8,9,10,11,12,13,14,15 The 
relapse risk seems to be lower in IBD patients who are in deep remission (clinical, 
biological and endoscopic remission) at the time of cessation of TNFα-blocking therapy 
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compared to those in clinical remission only.9 Available data are insufficient for giving 
strong recommendations on at what point safely cease TNFα-blocking therapy. Therefore 
the decisions should be based on assessment of the patient’s individual risks and benefits. 
In CD several factors have been investigated to identify patients who are more likely to 
achieve long-term remission after discontinuation of TNFα-blocking agents. The factors 
that have been associated with a higher risk of relapse are younger age, smoking, longer 
disease duration, fistulising phenotype, perianal disease, short duration of remission, 
previous surgical operation, endoscopically active disease, ileocolonic disease at 
diagnosis and previous TNFα-blocking therapy, high markers of inflammation and high 
infliximab trough level. On the other hand, mucosal healing, colonic CD, a shorter interval 
between disease diagnosis and starting anti-TNF, concomitant immunosupressive therapy 
and absence of antibodies to TNFα-blocking agents seem to decrease the risk of relapse 
after discontinuation of TNFα-blocking agents.6,7,10,12,13, 14,15,16 A study by Waught 
and co-workers shows that 35% of  the CD patients with a follow-up for nearly seven years 
after discontinuation of therapy remained in sustained clinical remission. No specific factor 
was associated with the duration of CD remission.17 In patients receiving TNFα-blocking 
agents for the prevention of post-operative CD recurrence, the risk of relapse after 
discontinuation is very high (>75%) and the ceasing decision should be based on very 
good reasons.18 Importantly, restarting of TNFα-blocking therapy for those who relapsed 
after stopping treatment seems to be effective and well-tolerated.5,6,9,10,12 
 
We have earlier published a prospectively collected 12-month data of cessation of TNFα-
blocking therapy in IBD-patients with deep remission.9 The aim of this study was to 
evaluate the long-term relapse rate after the first year of follow-up and the predictive 
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factors for relapse in this study population, as well as the response rate to TNFα-blocking 
agents after the restart of medication in the case of relapse.   
 
MATERIALS AND METHODS 
 
Patients and study design  
All 51 IBD patients in this follow-up analysis were primarily recruited in a prospective 
multicenter study which was carried out at nine gastroenterological centers in Finland 
during the period from February 2010 to June 2013.9  At the time of inclusion all patients 
were in deep remission (i.e. clinical, endoscopic and faecal calprotectin -based [FC 
<100µg/g] remission). After the primary study, one UC patient was dropped from the 
follow-up due to no available data on a patients' report. Clinical notes of all enrolled 
patients were retrospectively reviewed for this long-term follow-up. All patients had an 
established IBD diagnosis, had received TNFα-blocking maintenance therapy for a 
minimum of one year (the median duration of infliximab [IFX] therapy was 13 [n = 46, 
range 11-77] months and adalimumab [ADA] therapy 27 [n = 5, range 16-36] months), had 
been in corticosteroid-free remission over a 6-months period prior to the inclusion, were in 
clinical, FC-based (FC <100 µg/g) and endoscopic remission at the time of inclusion. Due 
to its small size, the subgroup IBDU of four patients was combined with the UC group. 
 
Given the retrospective design of this study, clinical disease activity was assessed by the 
physicians’ global assessment (asymptomatic patients vs. symptomatic patients indicating 
active IBD) in patients relapsing after the first year of follow-up and 12 months after the 
restart of TNFα-blocking therapy. At relapse endoscopic findings were scored, as in our 
earlier study 9, according to the SES-CD19 in CD and endoscopic Mayo score in UC and 
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IBDU.20 An SES-CD of 3-6 was defined as mildly active disease, 7-15 as moderately 
active disease, and ≥ 16 as severely active disease.21 Endoscopic Mayo subscore of ≥ 2 
defined active disease.22 
 
In a case of a clinical and/or endoscopic relapse after the first year of follow-up, TNFα-
blocking therapy was restarted at the same dose and frequency as prior to withdrawal in 
exception of two patients, whose relapses were treated with oral corticosteroids or 
mesalazine. Ileocolonoscopy was performed 12 months after the restart of TNFα-blocking 
therapy in exception of four patients with normal fecal calprotectin levels. Endoscopic 
activity was defined as mild, moderate, or severe by an experienced gastroenterologist.  
 
Fecal calprotectin assays 
FC was measured using the quantitative enzyme immunoassay (the CALPRO® 
Calprotectin ELISA Test  [ALP; Calpro AS, Lysaker, Norway]). The values quoted as 
normal were < 100 µg/g.23 
 
Statistics 
The Statistical Package for the Social Sciences (SPSS version 23) for Windows software 
(SPSS, Chicago, IL, USA) was used for data analyses. Fisher’s exact test was used to 
determine differences in binary variables. The significance was set at p < 0.05 and two-
tailed tests were used. Kaplan-Meier survival analysis was employed in estimation of 
relapse-free survival rates, and the log-rank test was used to determine the differences 
between the groups. The Cox regression of proportional hazards was used to calculate 
univariate hazard ratios for categorical and continuous variables. The results were given 
as percentages, as median and range, or as mean and standard deviation (SD). 
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Ethical statement 
The study protocol and all documents of the prior prospective multicenter study were 
approved by the ethics committee at Helsinki University Hospital and at each participating 
university central hospital. Because this follow-up study was a retrospective reviewing of 
patients' medical records, no separate application for ethics committee was needed. 
 
RESULTS 
The baseline characteristics are described in Table 1. As established in earlier publication, 
during the first 12-month follow-up, up to 33% of patients (5/17 [29%] CD and 12/34 [35%]) 
UC/IBDU) in deep remission relapsed.10 After the first relapse-free year, 14 of the 
remaining 34 IBD patients relapsed (40%; 5/12 [42%] CD and 9/22 [41%] UC/IBDU) during 
median follow-up period of 36 months (1-69; in CD 38 months [3-68] and in UC 35 months 
[1-69]). Of the14 relapsed patients, endoscopic data were available on 13 at the time of a 
relapse. Out of five relapsed CD patients, one experienced a severe clinical relapse 
without endoscopic documentation, two experienced  both clinical and endoscopic relapse 
(SES-CD 8 and10) and two experienced moderate endoscopic relapse without clinical 
symptoms mean (SES-CD 7 and 9). All UC patients experienced both clinical and 
endoscopic relapse (mean endoscopic Mayo score 2 [2-3]). 
 
The time-to-relapse curves of all patients are shown in Figure 1. No significant difference 
was found in the relapse rate between CD and UC/IBDU, p = 0.919. 
 
The risk factors for relapse 
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Based on univariate analysis (Cox model) risk factors such as diagnosis, gender, disease 
duration, localization, behavior, smoking, family history, previous surgery, the TNFα-
blocking agents used, concomitant medications or duration of the used TNFα-blocking 
agents were not associated with the risk of relapse, Table 2.  
 
Restarting TNFα-blocking therapy 
The response after restarting TNFα-blocking therapy was evaluated in all 29 of 51 IBD 
patients, Figure 2. The median time of follow-up after retreatment with TNFα-blocking 
agents was 12 (range 3-19) months. One relapsed UC patient was treated with 
corticosteroid and another with mesalazine instead of TNFα-blocking agents. After the 
restarting TNFα-blocking therapy, all except one UC patient achieved clinical remission or 
response at three months. During the follow-up period, three patients were operated on: 
one UC patient underwent colectomy less than two months after the restart of TNFα-
blocking therapy due to nonresponse and another UC patient underwent colectomy after 
one year of TNFα-blocking therapy due to loss of response. Furthermore, one CD patient 
underwent ileo-ceacal resection after one year of TNFα-blocking therapy due to a 
symptomatic stricture. After a restart of IFX, two UC patients experienced an infusion 
reaction (one during the second IFX infusion without anti-drug antibody measurement and 
the other one six months after restarting developing anti-drug antibodies) and were treated 
with another TNFα-blocking agent. In addition, despite a combination therapy with 
thiopurins, three patients (one CD and two UC patient) developed low concentrations of 
anti-drug antibodies, but achieved a clinical response by dose escalation (one CD and one 
UC patient) or by switching to another TNFα-blocking agent (one UC patient). Twelve 
months after the restart of TNFα-blocking therapy 20 patients (39%; 8 CD, 12 UC) were 
still in clinical remission. Six patients with CD and 11 patients with UC underwent a 12-
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month follow-up ileocolonoscopy, showing either endoscopic remission (4 CD, 9 UC) or 
mild activity (3 CD, 2 UC). The remaining three patients (2 CD, 1 UC) had normal 
calprotectin levels serving as surrogate markers to endoscopic remission.  
 
DISCUSSION  
 
It is well known that TNFα-blocking therapy is effective in inducing and maintaining 
remission in IBD patients with moderate to severe CD and UC and therefore, for 
responders the long-term maintenance therapy is recommended.24,25 However, life-long 
TNFα-blocking therapy in IBD patients in clinical remission or in deep remission is still 
questioned, since early treatment with an immunomodulator and/or TNFα-blocking agonist 
are nowadays recommended 26 and long-term safety issues are still debated. 
 
According to this follow-up study almost 60% of patients relapsed after a median follow-up 
time of 36 months. No statistically significant difference in the relapse rates between CD 
and UC was found. Several studies, mainly with CD patients, have been published on the 
duration of remission after a discontinuation of TNFα-blocking therapy, and only few of 
these studies have assessed endoscopic activity during a long-term follow-up. It is 
interesting to note, that across all studies reporting on anti-TNF withdrawal of adult IBD 
patients in clinical remission, despite heterogeneous study designs and patient 
populations, the one and two -year relapse rates were reasonably consistent ranging from 
21-39% and from 37%-56% respectively.6,7,8,9,10,11,12,13 These findings are in line 
with our results despite the fact that no baseline endoscopic remission was required in the 
majority of those earlier studies. However, recently published long-term data of the 
patients included in the STORI trial seem to indicate poorer remission rates after cessation 
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of IFX for sustained remission: the vast majority of CD patients (85%) had to restart the 
treatment over the course of time.27 The longest follow-up periods reported are 10 years 
in CD14 and 7 years in UC.15 Cumulative relapse rates in all studies rise over time.  
 
Cessation of TNFα -blocking therapy may be considered for patients with a low relapse 
risk. The relapse risk may be minimized using predictors that identify those at a clinically 
meaningful risk of relapse. Achieving deep remission is currently considered to be the 
most important protective factor in disease relapse after TNFα -blocking therapy 
withdrawal.28 Many of the risk factors shown in previous studies have been associated 
with incomplete remission with ongoing inflammatory disease activity at the time of 
discontinuation. It seems likely that not only the disease activity at the time of cessation of 
TNFα -blocking therapy but also previous disease history may have an impact on the risk 
of disease relapse following TNFα -blocking therapy withdrawal. Factors affecting the 
duration of a clinical remission after discontinuing anti-TNF therapy remain questionable 
even today. Moreover, it is very likely that patients' initial response to TNFα -blocking 
therapy and tendency to maintain sustained remission after therapy withdrawal is based 
on a patient-unique genetic type of IBD disease.29,30 Future studies are needed to 
analyze the correlation of patients' genotype and the duration of remission after 
discontinued TNFα -blocking therapy. As clear and widely accepted recommendations for 
discontinuing TNFα -blocking therapy are lacking, it has been stated that biological therapy 
should not be stopped in patients who have undergone multiple previous operations, 
demonstrated intolerance to conventional drugs or in whom the disease is difﬁcult to 
control.31 A multidisciplinary European expert panel (European Panel on the 
Appropriateness of Crohn’s Disease Treatment II, EPACT-II) considered discontinuing 
TNFα-blocking therapy to be appropriate after four years, but also after two years if the 
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patient was in deep remission.32 The results of our previous study suggested that 
withdrawal of TNFα-blocking therapy after one year could be possible in IBD patients with 
deep remission as the duration of TNFα-blocking therapy did not influence the relapse risk 
over time.9 Nevertheless, considering the possible adverse events after stopping TNFα-
blocking therapy, withdrawal should be considered carefully and discussed with the 
patient.  
 
After a drug-holiday, the risk of immunization resulting in infusion reactions and loss of 
response should be considered.33,34 Unfortunately, most of the studies report only short-
term outcomes and therefore more evidence is needed to demonstrate the real efficacy 
and safety of re-treatment. The studies including longer follow-up periods have reported 
remission rates from 80 to 92%.7,8 These findings are in line with our study, all but one of 
the patients achieved clinical remission or response at three months and the remission 
rate at one year was considerably high (97%). However, the risk of developing anti-drug 
antibodies may lead to infusion reaction and loss of response followed by severe 
problems. In our study, three patients underwent surgery due to no response to re-
treatment and five patients developed either anti-drug antibodies and/or experienced an 
infusion reaction. Taking this into account, withdrawal of TNFα-blocking therapy needs to 
be considered carefully.  
 
Our study has some limitations.The patient group is limited and heterogeneous and the 
number of patients in the subgroups low. Moreover, cut-off levels used for endoscopic 
remission (SES-CD score and endoscopic Mayo score) may have allowed mild 
endoscopic activity at baseline and also during the follow-up. However, we consider that 
low baseline FC value as another criterion of remission ruled out patients with notable 
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inflammatory activity.35 Furthermore, clinical and endoscopic data after one year of 
stopping TNFα-blocking therapy was not collected for the study purpose. Therefore clinical 
scores were not available for all patients at the time of relapse and clinical and endoscopic 
scores were not available after the restart of TNFα-blocking therapy for all patients. 
However, the strength of this study is a long term surveillance after cessation of TNFα-
blocking therapy in a clinical setting and endoscopic verification of a relapse. 
 
The long-term follow-up demonstrates a fairly high relapse rate after cessation of TNFα-
blocking therapy among IBD patients in deep remission. However, two out of five patients 
seem to remain in sustained clinical remission after cessation of TNFα-blocking therapy, 
but selecting these patients among potential relapsers is challenging. In relapsers, the 
response to a restart of TNFα antagonists seems to be effective and fairly well tolerated, 
even if the formation of anti-drug antibodies may result in to dose escalation or a change 
of TNFα-blocking agent. Therefore withdrawal of TNFα-blocking therapy should be 
considered carefully on individual bases. 
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A.    B.  
 
Time to relapse (Months) 
CD 
UC or IBDU 
Time to relapse (Months) 
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ADA; anti-drug antibody 
All patients
n = 51
Crohn's Disease
n = 17
Relapse 
at follow-up; n = 10
Infliximab 
therapy; n = 7
Continued infliximab therapy 
n = 5
Dose escalation due to ADA 
development; n = 1
Ileoceacal resection and withdrawal of 
infliximab; n = 1
Adalimumab 
therapy; n = 3
Remission
at follow-up; n = 7
Ulcerative colitis/IBDU
n = 34
Relapse at follow-up
n = 21
Infliximab 
therapy; n = 19
Continued infliximab therapy 
n = 13
Dose escalation due to  ADA development 
n = 1
Change to another TNFα-blocker due to an infusion 
reaction; n = 2 (ADA development n=1)
Change to another TNFα-blocker due to ADA 
development; n = 1 
Colectomy
n = 2
Corticosteroid 
therapy; n = 1
Mesalazine
therapy; n = 1
Remission at follow-up
n =  13
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Table 1. Patients' clinical and demographic characteristics at baseline. 
     
 Ulcerative colitis/ 
Inflammatory 
bowel disease 
unclassified   
n= 34 
Crohn’s disease 
n= 17 
Male/Female 19/15 8/9 
Age at onset (median, range) 26  (8-45) 23  (13-42) 
Age at induction (median, range) 32  (13-58) 33  (15-52) 
Active smoker, n (%) 4    (12) 4    (24) 
Disease duration (median, range) 6    (1-35) 10  (3-26) 
Previous bowel surgery, n (%)     8    (47) 
Disease behavior (Mb Crohn), n (%) 
Inflammatory (B1) 
Stricturing (B2) 
Penetrating (B3) 
B1 ± perianal disease 
B2 ± perianal disease 
B3 ± perianal disease 
  
11 (65) 
4   (24) 
1   (6) 
0 
1   (6) 
0 
Disease location  
 
Proctitis                  0 
Left colon             14 
Extensive colitis   20 
Ileum (L1)        1 
Colon (L2)       4    
Ileocolon (L3) 12 
Concomitant medications, n (%) 
    No concomitant medications 
    Mesalazine  
    Azathioprine/6-MP 
    Azathioprine/6-MP+ mesalazine 
    Methotrexate + mesalazine 
 
 
1    (3) 
4    (12) 
12  (35) 
17  (50) 
 
1   (6) 
3   (18) 
7   (41) 
5   (29) 
1   (6) 
Duration of TNFα-blocking therapy 
prior to cessation of therapy (months) 
    Infliximab (median, range) 
    Adalimumab (median, range) 
 
 
14  (11-78) 
 
 
32  (11-72) 
26 (16-36) 
TNFα-blocking therapy, n (%) 
    Infliximab 
    Adalimumab 
 
34  (100) 
 
12  (71) 
5    (29) 
6-MP = 6-Mercaptopurine 
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Table 2. Predictors for disease relapse in the study population. 
                            
Variable P- value Hazard 
Ratio 
95% CI 
lower 
 
upper 
Diagnosis; CD versus UC/IBDU 
Male sex 
0.919 
0.780 
1.042 
0.899 
0.469 
0.425 
2.316 
1.899 
Age at diagnosis 0.341 0.977 0.931 1.025 
Age at diagnosis; <25 y versus ≥25 y 0.073 0.492 0.227 0.069 
Age at diagnosis; < 20 y versus ≥ 20 y 0.090 0.508 0.232 1.112 
Localisation of CU 0.280 1.704 0.648 4.483 
Localisation of CD 0.345 1.000   
    L3 versus L1 0.243 3.888 0.398 38.017 
    L3 versus L2 0.464 0.453 0.054 3.778 
Disease behavior (CD)                          0.995 1.000   
    B1 versus B2 0.793 0.802 0.154 4.177 
    B1 versus B3 0.995 1.008 0.107 9.470 
    B1 versus B2 + perianal disease 0.242 2.391 0.555 10.298 
Smoking 0.252 1.000   
    No versus <10 cigarretts / day 0.125 0.383 0.112 1.306 
    No versus smoker  0.356 0.644 0.253 1.640 
    No versus smoker or previous smoker 0.117 0.524 0.233 1.177 
Age at induction 0.375 0.981 0.941 1.023 
Age at induction; < 30  versus ≥ 30 - 40 0.361 0.662 0.273 1.605 
Age at induction; < 30  versus ≥ 41 0.927 0.956 0.362 2.526 
Duration of the disease at induction 0.974 1.001 0.949 1.055 
Duration of the disease; > 5 - 10 years 0.173 1.876 0.760 4.630 
Duration of the disease; ≥ 11 years 0.447 1.451 0.556 3.784 
Previous surgery 0.577 0.739 0.255 2.140 
Positive family history 0.791 0.876 0.331 2.324 
TNF α-blocking therapy used; IFX vs. ADA 0.573 1.418 0.421 4.782 
Duration of the TNFα-blocking therapy; median 0.995 1.000 0.977 1.024 
CRP at discontinuation; median 0.450 0.935 0.785 1.113 
Hemoglobin at discontinuation; median 0.434 1.010 0.985 1.036 
 
CD = Crohn's Disease;  UC = Ulcerative Colitis;  IBDU = Inflammatory Bowel Disease type Unclassified; TNF 
= Tumour Necrosis Factor; IFX = Infliximab;  ADA = Adalimumab; CRP = C-reactive protein 
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